Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Theme
Making the Prevention Revolution Real - AIDS
- STD-AIDS 2018

About

    Allied Academies invites all the participants from all over the world to attend ‘International Conference on STD-AIDS’ which is going to be held on June 28-29, 2018 in Bangkok, Thailand. It includes prompt Oral talks, Keynote Presentations, Special Sessions, Workshops, Symposiums, Poster Presentations and Exhibitions.

    Allied Academic Publication is an amalgamation of several esteemed academic and scientific associations known for promoting scientific temperament. Established in the year 1997, Andrew John Publishing Group is a specialized Medical publisher that operates in collaboration with the association and societies. This publishing house has been built on the base of esteemed academic and research institutions including The College of Audiologists and Speech Language Pathologists of Ontario(CASLPO), The Association for Public Safety Communications Officials of Canada (APCO), The Canadian Vascular Access Association (CVAA), The Canadian Society of Internal Medicine (CSIM), The Canadian Hard of Hearing Association (CHHA), Sonography Canada, Canadian Association of Pathologists (CAP-ACP) and The Canadian Association of Neurophysiologic Monitoring (CANM).

Why to Attend?

    The sector of AIDS and STDs is growing apace and its development is creating tremendous impacts in medical sciences and prescription drugs. The importance and significance may be gauged by the actual fact that it's created brobdingnagian advancements over the course of your time and is constant to influence varied sectors. STD-AIDS program can showcase new knowledge domain and offers a platform for professionals and community members to interact in a very structured dialogue on the main problems. The collective goal are going to be to share scientific discoveries and clinical care on HIV and retroviral diseases, HIV designation and medical care that will embrace varied strategies to techniques to diagnose HIV, HIV drug discovery, infectious agent and microorganism STDs, STIs, like Herpes, Syphilis, HPV etc. ways for HIV and STDs interference, ethics etc. As HIV/AIDS is Associate in Nursing horrifying concern throughout the planet, STD-AIDS-2018 can in the main concentrate on problems like Primary HIV Infection, Transmission and demolition problems except this HIV Co-infection, HIV Current pharmaceutical style would cowl the experimental medication developed.

Target Audience:

  • Director
  • HOD
  • Business Delegates
  • Doctors
  • Professor
  • Researcher
  • Microbiologists
  • Bacteriologists
  • Virologists
  • Epidemiologists
  • Health care professionals
  • STD-AIDS associations and societies
  • Academicians
  • Students

Welcome Message

    We are delighted to welcome you to the ‘International Conference on STD-AIDS’ which is going to be held on June 28-29, 2018 in Bangkok, Thailand.

    The field of STD (Sexually Transmitted Diseases) is growing rapidly and its development is making tremendous impacts in medical sciences and pharmaceuticals. The importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors.

    STD-AIDS 2018 conference could be a global platform for sharing and exploring new areas of research and development and to assess rising technologies in the field of STD-AIDS. There will be many seminars, workshops, and technical sessions take place in this Allied Academies which will catch the attention of the professionals to attend the conference further which will enormously enrich our knowledge in understanding the current requirements of the global Sexually Transmitted Diseases. The expert will get an excellent opportunity to give many presentations and lectures on different topics.

    So, we invite all the Doctors, Scientists, Professors and Researchers in the field of STD, STI, HIV/AIDS and its related areas people who believe in cure to explore their research, case studies and practitioners at STD-AIDS 2018.

Sessions/Tracks

Track.1: STD & STI

    STDs are infections that are passed from one person to a different person during vaginal, anal, and oral sex. They’re really common, and lots of people who have them don’t have any symptoms. Sexually transmitted diseases can be unsafe, however the great news is that getting tested is no big deal, and most STDs are simple to treat. Symptoms and signs of disease may include vaginal discharge, penile discharge, ulcers on or around the genitals, and pelvic pain. The causes of STDs are bacteria, parasites, yeast and viruses. Sexually transmitted contaminations, likewise alluded to as sexually transmitted diseases (STD) and venereal diseases (VD), are diseases that are usually spread by sex, particularly vaginal intercourse, butt-centric sex or oral sex. Most STIs initially do not cause symptoms.  This results in a greater risk of passing the disease on to others. Side effects and indications of infection may incorporate vaginal release, penile release, ulcers nearby the private parts, and pelvic agony. STIs acquired before or during birth may result in poor outcomes for the baby. Some STIs may cause problems with the ability to get pregnant. Most STIs initially do not cause symptoms. This results in a greater risk of passing the disease on to others.

Track.2: HIV/ AIDS

    HIV stands for human immunodeficiency virus. The infection can prompt AIDS, or AIDS, if not treated. Unlike some other viruses, the human body can’t get rid of HIV completely, even with treatment. So once you get HIV, you have it for life. HIV assaults the body's safe framework, particularly the CD4 cells (T cells), which enable the resistant framework to fend off contaminations. Untreated, HIV reduces the number of CD4 cells (T cells) in the body, making the person more likely to get other infections or infection-related cancers. After some time, HIV can decimate such a significant number of these cells that the body can't fend off contaminations and sickness. These opportunistic infections or cancers take advantage of a very weak immune system and signal that the person has AIDS, the last stage of HIV infection. Helps is the most serious period of HIV contamination. People with AIDS have such badly damaged immune systems that they get an increasing number of severe illnesses, called opportunistic infections. AIDS is not a virus but a set of symptoms (or syndrome) caused by the HIV virus. A man is said to have AIDS when their invulnerable framework is excessively frail, making it impossible to fend off contamination, and they build up certain characterizing side effects and diseases. This is the last phase of HIV, when the contamination is exceptionally best in class, and if left untreated will prompt passing.

Track.3: Understanding and Identifying HIV

    There are a number of infections and cancers that can develop in people who are living with HIV. There are infections that can be life threatening. These are also known as opportunistic infections. The more common life-threatening infections include a lung infection called Pneumocystis pneumonia (PCP), an eye infection caused by Cytomegalovirus (CMV), a brain infection called toxoplasmosis, and a generalized infection called Mycobacterium Avium Complex (MAC). Cancers that are more common include Hodgkin’s lymphoma, lung cancer, skin cancer, anal cancer, cervical and vaginal cancer in women and testicular and prostate cancer in men. These cancers can often be successfully treated if they occur in people with HIV who maintain healthy immune systems with HIV treatment. Antiretroviral treatment (ART) is the utilization of HIV medications to treat HIV disease. HIV medicines protect the immune system by blocking HIV at different stages of the HIV life cycle. HIV medicines are grouped into different drug classes according to how they fight HIV. Each class of drugs is designed to target a specific step in the HIV life cycle. ART consolidates HIV medications from no less than two distinctive HIV sedate classes, making it exceptionally successful at keeping HIV from duplicating. Having less HIV in the body protects the immune system and prevents HIV from advancing to AIDS. ART also reduces the risk of HIV drug resistance. ART can't cure HIV, however HIV drugs enable individuals with HIV to live more, beneficial lives. HIV medicines also reduce the risk of HIV transmission.

Track.4: Infertility & Birth Defects

    The relationship between infertility, birth defects with infection is long known. A symptomatic infections caused by certain infections are more devastating as the absence or lack of symptoms prevents the patients from seeking timely medical intervention which consequently leads to chronic damage of the pelvic organs. Chlamydia, among the most widely recognized sexually transmitted infections, influences an expected 100,000 pregnant ladies every year, as per the Centers for Disease Control and Prevention. Premature birth of the baby which happens before 37 weeks of the pregnancy. Birth defects which is the abnormal shapes and function of the baby. PID, or Pelvic inflammatory disease, is a contamination that happens in organs of a ladies' conceptive framework that incorporate the uterus, ovaries, fallopian tubes, and cervix. Chlamydia and gonorrhea are foremost causes of pelvic inflammatory disease (PID) and infertility.  A low sperm   motility and low sperm count are indicators of STDs condition in male that may lead to infertility. Trichomoniasis can adversely affect a woman’s ability to conceive a child if left untreated. This is one of the mainstream system in which sperm is specifically infused into the egg — intra-cytoplasmic sperm infusion, or ICSI — was related with an expanded danger of birth deserts, as was home utilization of an ovulation incitement prescription.

Track.5: HIV & Cancer

    HIV itself assumes a part in how malignancy develops in individuals who are HIV-positive. HIV attacks the immune system, which protects the body from infections and disease. A weaker immune system is less able to fight off diseases, like cancer. Individuals with HIV regularly have debilitated resistant frameworks which simply they will have a more noteworthy shot of getting growth. Here are some reasons why cancer seems to be more common among people with HIV: 1. People with HIV and AIDS are living longer. HIV drugs are helping individuals with HIV live more, more advantageous lives. But their immune systems do not get fully healthy. As people with HIV live longer, their chances of having other health problems, like cancer, increase. 2. HIV and other viruses work together. Having HIV and a debilitated safe framework makes is less demanding for different infections to remain alive in your body. HIV and these other viruses work together to help cancer cells start growing. Once cancer starts in people with weakened immune systems, it grows faster than in healthy people. Some of these viruses are:

  • Hepatitis B and Hepatitis C
  • Human Papillomavirus (HPV)
  • Herpes
  • Epstein-Barr Virus (EBV)

Track.6: HIV & Cardiovascular Disease

    Cardiovascular disease (CVD) is a class of illnesses that include the heart or veins. Cardiovascular disease includes coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack). With the appearance of antiretroviral treatment (ART) and expanded survival, HIV infected individuals are currently in danger for infections of maturing including cardiovascular illness (CVD). In the ART era, multiple large cohort studies have found that HIV infection is associated with an increased risk of acute myocardial infarction (AMI), ischemic stroke, and heart failure. Cardiovascular sickness (CVD) incorporates a gathering of issues identified with the heart or to veins. CVD includes coronary heart disease, angina, cerebrovascular disease, rheumatic heart disease, high blood pressure, peripheral artery disease, congenital heart disease and heart failure. Around the world, CVD is the reason for around 30% of all passings. Studies extend from hereditary and sub-atomic investigations of the components of cardiovascular ailment to investigations of vascular properties, way of life intercessions, and responsiveness to preventive pharmacotherapy.

Track.7: Trichomoniasis, Syphilis

    Trichomoniasis is a sexually transmitted disease or Sexually Transmitted  Infection (STI) caused by a parasite. Trichomonas infection can affect women or men and is spread via sexual contact. Many people who have the infection have no symptoms, but when symptoms occur, they include vaginal or urethral (in men) discharge that may appear greenish and frothy, burning on urination, discomfort during sex and itching in the genital area. Syphilis is also a sexually transmitted disease that can have very serious complications when left untreated, but it is simple to cure with the right treatment. Symptoms in adults are divided into stages. These stages are essential, optional, dormant, and late syphilis. Syphilis can be spread by direct contact with a syphilis sore during vaginal, anal, or oral sex. Sores can be found on the penis, vagina, anus in the rectum, or on the lips and in the mouth. Syphilis has been called 'the considerable imitator' since it has such a large number of conceivable manifestations, a significant number of which resemble indications from different sicknesses. The painless syphilis sore that you would get after you are first infected can be confused for an ingrown hair, zipper cut, or other seemingly harmless bump. Be that as it may, if not treated quickly, the infant may create major issues inside fourteen days. Untreated babies can have health problems such as cataracts, deafness, or seizures, and can die.

Track.8: HIV in Women

    HIV stands for human immunodeficiency virus. It hurts your safe framework by annihilating the white platelets that battle disease. HIV often spreads through unprotected sex with an infected person. Women can get it more easily during vaginal sex than men can. HIV may also spread by sharing drug needles or through contact with the blood of an infected person. One-third of all new HIV cases occur in women. Sexual transmission from an infected male partner is the most common mode of transmission in women. The symptoms of HIV in women are fever and night sweats, swollen lymph nodes, sore throat, skin rash, muscle soreness and joint pain, fatigue, nausea/vomiting. Upon infection, it may take individuals with HIV 2-4 weeks to exhibit symptoms. Often these symptoms are mistaken for a common cold or flu, rather than HIV. Around 80 percent of people with an intense HIV contamination will encounter influenza like manifestations. That being said, sometimes it can take years for symptoms to appear. This is why it is so important for you and your partner to always get tested before beginning a new sexual relationship. Getting tried for HIV enables ladies to look for required treatment sooner and stops the spread of the infection to others.

Track.9: HIV & Bone Damage

    Bone is living tissue that is in a steady condition of recovery, much like the kidneys, heart, and different organs of the body. Bone consists of two important components: collagen and mineral. Bone is mostly made up of collagen. Collagen provides a soft framework and gives bones necessary flexibility. The mineral part incorporates calcium and phosphate and solidifies the collagen structure. Bones must maintain a balance of collagen and mineral so that they are strong, yet flexible enough, to withstand stress. Osteoporosis and osteopenia are familiar terms to many older adults. A finding of osteoporosis, a genuine loss of bone mass, can expedite a great deal of nervousness, as it by and large implies that a man's bones have turned out to be weaker and will probably break. And while a diagnosis of osteopenia—a less serious loss of bone—does not mean the same thing as an osteoporosis diagnosis, it can be of concern just the same. Shockingly, numerous HIV-constructive individuals—a considerable lot of whom are more youthful than the individuals who regularly encounter debilitating bones—are discovering that they, as well, have osteopenia or osteoporosis. Osteoporosis is known as a silent disease, as it does not usually cause any symptoms. Many individuals don't discover that they have osteoporosis until the point when they have endured a bone crack.

Track.10: HIV & Aging

    Today, more than half of all people living with HIV in the United States are 50 years or older. This is mostly because people are living much longer with HIV thanks to effective antiretroviral (ARV) therapy, and that’s good news. The terrible news is inquire about progressively demonstrates that illnesses that ordinarily strike HIV-antagonistic individuals in their 70s are happening in individuals with HIV in their 50s. These concerns have brought the issue of aging with HIV to center stage. One of the biggest unanswered questions is why this is occurring. Whether it’s heart attacks, bone fractures, kidney disease or certain cancers, the rates of these conditions in HIV-positive people are alarming. It’s unclear how much HIV contributes to these conditions and how much is explainable by other factors such as smoking, HIV drugs and co-infection with other viruses. In any case, most HIV-constructive individuals can do a considerable amount to moderate the maturing procedure and make preparations for the beginning of age-related disease. HIV isn’t unique in this regard, however. HIV differs from many other diseases is that in 99 percent of HIV-positive people, the immune system doesn’t control the virus very well. This constant state of battle, where the virus reproduces and the body fights against it, keeps the immune system chronically in high alert, a syndrome called inflammation.

Track.11: Sex Worker Health & Rights

    Sex workers are frequently derided, minimized and criminalized by the social orders in which they live. In various ways, these factors contribute to their vulnerability to HIV. Even though sex work is at least partially legal in some countries, the law rarely protects sex workers. Around the globe, there is a serious absence of enactment and approaches securing sex specialists who might be in danger of viciousness from both state and non-state performing artists, for example, law authorization, accomplices, relatives and their customers. Sex workers are 10 times more in danger of HIV contrasted and the all-inclusive community, because of an improved probability of being financially powerless, unfit to arrange predictable condom utilize, and encountering brutality, criminalization and underestimation. Where HIV prevention programs are available they are generally well received, however sex workers often face many barriers in accessing them. HIV prevention services that are sex-worker led and community based are proven to be most effective when they address the legal and social barriers that affect sex workers. 

 Track.12: Current Focus on Virology

    Virology is the examination of diseases – parasitic particles of inherited material contained in a protein coat, submicroscopic and contamination like authorities. Virology is often considered a part of microbiology or of pathology. Infections and viral illnesses have been at the focuses of science, horticulture, and prescription for centuries and some of our most noteworthy difficulties and triumphs have included virology. Our STD AIDS conference is bringing experts from the field of HIV, STD AIDS, STIs Vaccines, virology and Immunology or discussion of the latest advances and ideas and to stimulate interdisciplinary interactions. Meeting like our own will accelerate of the advancement of powerful treatments for viral clutters. Curtailing the spread of infectious disease traditionally has been accomplished through use of vaccines, antibiotics, antiviral drugs, and public health measures. But in the face of challenges like drug-resistant microbes and the emergence of HIV, future answers hinge on progressive research in molecular virology and microbiology. HIV infection and AIDS have become a major worldwide public health problem. According to WHO approximately 35 million people worldwide living with HIV/AIDS in 2013, unaware of the outcomes. AIDS is a perpetual, conceivably dangerous condition caused by the human immunodeficiency infection (HIV) which harms the insusceptible framework and, meddles with body's capacity to battle the living beings that reason illness.

Track.13: Lived Experience of HIV

    Finding that you are HIV-positive can be a champion among the most troublesome experiences you involvement in life. You may feel scared, sad or even angry – this is OK, and a completely natural part of coping with something that can be life changing. Be that as it may, recall, HIV doesn't need to stop you living a long, glad and satisfying life. With the right treatment and support, it is possible to live as long as the average person. There is a considerable measure of confusions about being living with HIV. At last, everybody's lives are diverse – how you adapt to your determination and how you push ahead will be remarkable. It is a guideline, which advocates for the dynamic and significant cooperation of individuals living with HIV in the outline, innovative work, execution, checking and assessment of all approaches and software engineers that influence their lives. The interest and authority of individuals living with HIV in forming the way we consider HIV and in managing the work we do expands the nature of our work and adds to the objectives we are attempting to accomplish.

Track.14: Awareness & Knowledge

    STDs (Sexually transmitted diseases) are a noteworthy medical issue influencing for the most part youngsters, in creating, as well as in created nations. We conducted this systematic review to determine awareness and knowledge of school-going male and female adolescents in Europe of STDs and if possible, how they perceive their own risk of contracting an STD. Aftereffects of this survey can enable call attention to territories where STD to chance correspondence for youths should be moved forward. HIV/AIDS has emerged as the single most formidable challenge to public health, human rights, and development in the new millennium. The epidemic of HIV/AIDS is now progressing at a rapid pace among young people. Many adolescents around the world are sexually active and because many sexual contacts among them are unprotected, they are at a risk of contracting sexually transmitted diseases (STDs) including HIV/AIDS. It was observed that the knowledge of the school students was quite satisfactory for most of the variables like modes of transmission, including mother-to-child transmission of the disease. However, schools should come forward to design awareness campaigns for the benefit of the students.

Track.15: Prevention & Treatment

    Viral infections treatment such as HIV comprises patient care and ethical support including antiretroviral therapy. Bacterial infections can be treated by administering antibiotics to the patients. Bacterial STDs can be cured with antibiotics if treatment begins early enough. Viral STDs cannot be cured, but can manage symptoms with medications. Yeast infections can be primarily treated by sterilization methods. Getting vaccinated early, before sexual exposure, is also effective in preventing certain types of STIs. There is no cure for HIV, but with proper treatment called “antiretroviral therapy” (ART), it is possible to maintain a low viral count and live a nearly normal life expectancy of up to 50 years. The most ideal approach to avert HIV/AIDS is by maintaining a strategic distance from high-chance exercises related with illness transmission, for example, dangerous sex and needle sharing. HIV drugs include: Reverse transcriptase inhibitors. HIV uses its own reverse transcriptase enzyme to synthesize DNA from RNA. The function of this enzyme is required for viral replication in the host cell. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) directly inhibit the activity of this enzyme. Nucleoside reverse transcriptase inhibitors (NRTIs) are faulty mimics of the building blocks used by the enzyme to synthesize DNA. Protease inhibitors. HIV protease is another protein that is basic to the viral life cycle. Protease inhibitors are molecules that block the activity of this enzyme. Integrase inhibitors. The integrase enzyme allows HIV to insert its genetic material into its host cells. Molecules that inhibit HIV integrase block this essential step. Entry/fusion inhibitors. These medications keep the infection from connecting to and entering CD4+ T cells.

Track.16: Prevention of Mother to Child Transmission

    Mother-to-child transmission of HIV is the spread of HIV from a HIV-contaminated lady to her tyke amid pregnancy, labor (likewise called work and conveyance), or breastfeeding (through breast milk).  Mother-to-child transmission of HIV is also called perinatal transmission of HIV. Mother-to-child transmission is the most widely recognized way that kids end up noticeably tainted with HIV. Mother-to-tyke transmission is the most widely recognized way that kids wind up noticeably tainted with HIV. Pregnant women with HIV receive HIV medicines during pregnancy and childbirth to prevent mother-to-child transmission of HIV. In a few circumstances, a lady with HIV may have a planned cesarean conveyance (now and again called a C-segment) to avert mother-to-kid transmission of HIV amid conveyance. Children destined to ladies with HIV get HIV prescription for 4 to a month and a half after birth. The HIV pharmaceutical lessens the danger of contamination from any HIV that may have entered an infant's body amid labor. Since HIV can be transmitted in bosom drain, ladies with HIV living in the United States ought not breastfeed their infants. In the United States, baby formula is a safe and healthy alternative to breast milk. In the event that a lady takes HIV prescriptions amid pregnancy and labor and her infant gets HIV pharmaceutical for 4 to a month and a half after birth, the danger of transmitting HIV can be brought down to 1% or less.

Track.17: Case Study: Infectious Disease & HIV

    An entire investigation of momentum inclines in the irresistible ailments remedial and demonstrative market, industry development drivers, propelled treatments and restrictions. It provides market projections for the coming years. It includes analysis of recent developments in technologies of infection diagnosis and treatment. Contextual analyses concentrate on intense respiratory contaminations, diarrheal sicknesses, hepatitis, HIV, tuberculosis, sexually transmitted infections, jungle fever, and other vector-borne ailments. Report of a 45-year-old male farmer, a resident in the forest zone of Pernambuco, who was diagnosed with human immunodeficiency virus (HIV) in 1999 and treated using antiretroviral (ARV) drugs. In 2005, the first episode of visceral leishmaniasis (VL), as assessed by parasitological diagnosis of bone marrow aspirate, was recorded. When admitted to the hospital, the patient presented fever, hepatosplenomegaly, weight loss, and diarrhea. Since then, six additional episodes of VL occurred, with a frequency rate of one per year. In 2011, the patient presented a disseminated skin lesion caused by the amastigotes of Leishmania, as identified by histopathological assessment of skin biopsy samples. In 2005, he was treated with N-methyl-glucamine-antimony and amphotericin B deoxycholate. However, since 2006 because of a reported toxicity, the drug of choice was liposomal amphotericin B. As recommended by the Ministry of Health, this report emphasizes the need for HIV patients living in VL endemic areas to include this parasitosis in their follow-up protocol, particularly after the first infection of VL.

Track.18: Drug Discovery & Research

    Medication disclosure is the procedure through which potential new prescriptions are recognized. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology. The identification of viral and cellular drug targets is essential for fueling the drug development pipeline. Early medication disclosure endeavors focused on a moderately modest number of viral targets, for example, HIV switch transcriptase (a compound that catalyzes the union of viral DNA inside contaminated cells from the RNA layout conveyed by irresistible virions) and HIV protease (a chemical that cuts and procedures viral antecedent proteins permitting virion development). Treatment regimens containing combinations of reverse transcriptase and protease inhibitors, commonly known as highly active antiretroviral therapy, or HAART, revolutionized the treatment of people with HIV by markedly lowering viral load and decreasing the incidence of AIDS-associated opportunistic infections. In the past most drugs have been discovered either by identifying the active ingredient from traditional remedies or by serendipitous discovery. Another approach has been to see how sickness and disease are controlled at the sub-atomic and physiological level and to target particular substances in view of this information. The process of drug discovery involves the identification of candidates, synthesis, characterization, screening, and assays for therapeutic efficacy. Once a compound has demonstrated its incentive in these tests, it will start the procedure of medication improvement preceding clinical trials.

Track.19: Vaccines & Vaccination

    A HIV vaccine is an antibody which would either secure people who don't have HIV from getting that infection, or generally may have a remedial impact for people who have or later contract HIV/AIDS. Currently, there is no effective HIV vaccine but many research projects managing clinical trials seek to create one. There is evidence that a vaccine may be possible. Protection medicines, for example, antiretroviral medications have been put into utilization to help forestall contamination, however don't act and additionally an Vaccine would. Work with monoclonal antibodies (MAB) has shown or proven that the human body can defend itself against HIV, and certain individuals remain asymptomatic for decades after HIV infection. Potential possibility for antibodies and beginning time comes about because of clinical trials have been declared. Alternative medical treatments to a vaccine do exist. Highly active antiretroviral therapy (HAART) has been highly beneficial to many HIV-infected individuals since its introduction in 1996 when the protease inhibitor-based HAART initially became available. HAART permits the adjustment of the patient's indications and viremia; however they don't cure the patient of HIV, nor of the manifestations of AIDS. And, importantly, HAART does nothing to prevent the spread of HIV by people with undiagnosed infections. Acquaintance of more secure sex measures with stop the spread of AIDS has demonstrated troublesome in the most noticeably awful influenced nations. Therefore, an HIV vaccine is generally considered as the most likely, and perhaps the only way by which the AIDS pandemic can be halted. In any case, after more than 30 years of research, HIV-1 remains a troublesome focus for a Vaccine.

Market Analysis

Summary: 

    STD-AIDS 2018 is the stage to pick up and share the information in the new Medical improvements alongside the fields of STI and HIV/AIDS. This conference brings together Doctors, Professors, Researchers, Scientists, Microbiologists, Bacteriologists, Virologists, Associations and Societies, Epidemiologists, Health care professionals, Research scholars, Medical colleges, Infectious Diseases Researchers, Viral Diseases Researchers, Pharmacists, Physicians, academia, studentsin all the areas of STD-AIDS and provides an international forum for the spreading of approved research results, new ideas and practical developments. We are honored to invite you all to attend for the ‘International Conference on STD-AIDS’, which is going to be held during June 28-29, 2018 in Bangkok, Thailand.

    The organizing committee is preparing for an exciting and instructive gathering program including plenary lectures, symposia, prompt keynote displays, Oral talks on an assortment of subjects, poster presentations, exhibitions and different projects for participants from everywhere throughout the world. We invite you to join us at the prestigious conference STD-AIDS 2018, where you will be sure to have a meaningful experience with scholars and eminent personalities from around the world. All members of the STD-AIDS 2018 organizing committee are looking forward to meeting you in Bangkok, Thailand.

Importance & Scope:

    In the past few decades, AIDS is one of the major problems across the world. It has been reported that by the end of 1999, the AIDS epidemic had left behind a cumulative total of 11.2 million orphans, defined as children who have lost their mothers before reaching the age of 15 (UNAIDS, 1999). The World Health Organization further estimates that 5.3 million people, including 600,000 children under age of 15, became infected with the virus that causes AIDS this year (Olson, 2000). Specifically, the data coming out of the Caribbean region show that HIV/AIDS has been moving into younger and younger population groups. About of% 83 AIDS cases are diagnosed in people between the ages of 15 and 54 and almost half of these cases are diagnosed in people 23 to 34 years old. Mindful of the links between health behavior and the context of family and culture, the authors maintain that intervention strategies in West Indian communities like Grenada must take into account the broader cultural context. The goal is to set the contextual framework for the development of culturally responsive HIV/AIDS education and prevention programs targeted to young people and adolescents. Specific strategies for working with parents and adolescents from this cultural group are recommended. The Centers for Disease Control and Prevention (CDC) estimates that 1.2 million people are infected with HIV in the United States and that 1 in 5 (20 percent) are unaware that they are infected. In 2010, over 47,000 people were newly diagnosed with HIV, the majority of whom were men. HIV disease is over-spoken to in the African-American people group: African-Americans make up just about one-portion of the recently analyzed cases, followed by Whites and Hispanics.



    Compelling medications have significantly decreased the quantity of deaths from AIDS since peak years of the epidemic (1993– 1998); be that as it may, more than 17,000 individuals still died from AIDS-related ailments in 2009. Truth be told, even among those determined to have HIV, a significant extent don't get legitimate care or stay in treatment (see figure). Also, the pattern of individuals living longer with HIV shows new, long -term health services challenges for this population.

The topics to be covered by STD-AIDS include, but are not limited to:

  • STD & STI
  • HIV/ AIDS
  • Understanding and Identifying HIV
  • Infertility & Birth Defects
  • HIV & Cancer
  • HIV & Cardiovascular Disease
  • Trichomoniasis, Syphilis
  • HIV in Women
  • HIV & Bone Damage
  • HIV & Aging
  • Sex Worker Health & Rights
  • Current Focus on Virology
  • Lived Experience of HIV
  • Awareness & Knowledge
  • Prevention & Treatment
  • Prevention of Mother to Child Transmission
  • Case Study: Infectious Disease & HIV
  • Drug Discovery & Research
  • Vaccines & Vaccination

Why Bangkok:

    Bangkok has been Thailand's predominant city since the eighteenth century. Established as the capital in 1767 after the fall of the ancient city of Ayutthaya, Bangkok is located on one of southeastern Asia's most important rivers, the Chao Phraya. In the 1990s, Bangkok experienced fast modernization, developing to around ten million individuals, making this the main significant city in a nation of towns and residential communities. Bangkok's ancient palaces and Buddhist temples contrast with high rises and traffic jams. Dense air pollution blankets the city. In fact, police directing traffic are required to wear masks. In any case, regardless of present day issues, Bangkok is a noteworthy vacationer goal, drawing a large number of guests every year.

    According to the Tourism Authority of Thailand, Thailand received 30 million tourists, of which up to 16 million or 53%, came for medical and wellness treatments.  Tourists who specifically sought medical treatments came in at 857,086 and about 15 million came for wellness (for a wide range of services from massage to health food). International patients are from the Middle East countries such as Oman and United Arab Emirates, Cambodia, Myanmar, China, U.S. and European countries.  Private hospitals in Bangkok serve more than 43% of medical tourists coming to Asia. Thailand’s medical device market was estimated at $1.259 billion in 2016 and is expected to grow at least 10% in 2017.  In 2016, imports of medical devices increased 10.4% and exports of medical devices increased 7%, reflecting steady growth in Thailand’s healthcare sector despite the global and domestic economic downturn.  As a market leader, U.S. device makers provide approximately one-fourth of the imported medical devices. The Thai medication market will keep on growing through 2020 and new laws and infection patterns give astounding chances to remote pharmaceutical organizations to succeed.

Major Universities in Bangkok:

  • Kasetsart University  
  • Chulalongkorn University      
  • King Mongkut's University of Technology Thonburi
  • Thammasat University           
  • Sripatum University   
  • Assumption University          
  • Srinakharinwirot University   
  • King Mongkut's Institute of Technology Ladkrabang          
  • National Institute of Development Administration   
  • King Mongkut's University of Technology North Bangkok 
  • Silpakorn University  
  • Ramkhamhaeng University    
  • University of the Thai Chamber of Commerce          
  • Bangkok University   
  • Mahachulalongkornrajavidyalaya University

Market in Thailand:

    In Asia, Thailand stays one of the nation’s hardest hit by the HIV scourge. Currently, 440,000 people are living with HIV and approximately 1,250 people die each year from HIV-related causes. Thailand’s population of more than 60 million, in 2016 it was estimated that 450,000 people were living with HIV and that 6,400 people died of AIDS-related illnesses. After sub-Saharan Africa, Asia and the Pacific is the region with the largest number of people living with HIV, with Thailand accounting for approximately 9%. Although the HIV epidemic is declining, certain groups have much higher rates of HIV compared to the general population. Those most affected are men who have sex with men, male and female sex workers, transgender people and people who inject drugs. Spouses of these populations and people living with HIV, migrant workers and prisoners are also more vulnerable to HIV than others.

Highlights:

  • Thailand has one of the biggest HIV prevalences in Asia and the Pacific, representing 9% of the locale's aggregate HIV populace.
  • Thailand hopes to be one of the first countries to end aids by 2030, however to achieve this more must be done to target young people and key affected populations.
  • Thailand is the first country to effectively eliminate mother to child transmissions, with a transmission rate of less than 2%.
  • Despite the fact that the pandemic is in decay, predominance stay high among key influenced gatherings.

    An investigation has demonstrated that almost 10 million individuals stayed away from HIV transmission in view of early intercession programs with key influenced populaces in the vicinity of 1990 and 2010. Between 2005 and 2016, AIDS-related deaths declined by almost two thirds. There were 6,400 new HIV infections in Thailand in 2016. Most will have happened through unprotected sex, which is assessed to represent 90% of all new HIV diseases. Unsafe injecting drug use is the second biggest transmission route. Although the country is often praised for its highly successful efforts to curb the spread of HIV among sex workers and their clients, particularly through the world-renowned 100% Condom Use Program, its response to HIV among men who have sex with men (MSM) has been limited. The prevalence of HIV among MSM has risen sharply from around 6% in the late 1990s to as high as 20-30% currently, and continues to grow. From 2012-2016, it is estimated that 39,000 people will be infected with HIV in Thailand. MSM make up 44% of these new HIV cases, with around 33% of the contaminations happening in Bangkok. The proportion of MSM among new HIV cases could go as high as 59% within the next 10 years, according to estimates made by the Asian Epidemic Model. The most astounding predominance among transients in Thailand was found in the angling business, with rates of 2% among anglers and 2.3% among fishery laborers, contrasted with HIV commonness of 1.1% and 0.74% among assembly line laborers and homestead specialists, separately.


    A 2015 investigation of youngsters from key influenced populaces discovered testing rates to shift broadly between bunches – from a low of 12% (youthful female sex specialists situated in Chiang Mai) to a high of 73% (young fellows who engage in sexual relations with men situated in Bangkok). Overall, it found young female sex workers to be the least likely to test. New methodologies have been acquainted with increment access to and interest for HTC among key influenced populaces, including the accompanying:

  • Implementing community-based HTC to expand outreach work
  • Ensuring that HTC outlets provide same-day results.

    Thailand provides antiretroviral treatment (ART) for free as part of the country’s universal health insurance scheme. It is one of only two countries in Asia and the Pacific that has more than 50% of people living with HIV on ART, the other being Cambodia. In 2016, 68% of adults who are eligible for treatment were receiving it, alongside more than 86% of children.

Thailand’s future of HIV and AIDS:

    In spite of the fact that Thailand gained gigantic ground with HIV aversion in the 1990s, the decrease in HIV pervasiveness has backed off lately. Access to prevention services and behaviour-change communication hasn’t been enough to significantly reduce the rate of new infections, particularly among men who have sex with men. NAC's 2015-2019 technique expresses that Thailand will be one of the main nations on the planet to effectively end AIDS by 2030, and the principal nation in the area. Indeed, from 2015 the Ministry of Public Health increased its budget to prepare for implementing its strategy to end AIDS. Its spending commitments must remain a focus if real progress is to be made.

    Furthermore, to be in with a real chance of ending AIDS by 2030, Thailand will need to give significant focus to new and innovative strategies to reach both young people and key affected populations, particularly men who have sex with men.

Market Growth in Thailand:

    According to the International Monetary Fund (IMF), Thailand’s GDP based on Purchasing Power Parity (PPP) exceeded $1.1 trillion dollars in 2016, making Thailand the second largest economy in Southeast Asia after Indonesia, which has a GDP (PPP) of $3 trillion. In 2016, Thailand’s GDP grew by 3.2%, compared to 1.6% in the US and 2% in the European Union (IMF). The Asian Development Bank predicts Thailand’s GDP will grow 3.5% and 3.6% in 2017 and 2018, respectively.

    Thailand imported over $2.2 billion in pharmaceuticals in 2016, a significant increment from $1.8 billion only two years back. In 2016, over 65% of Thailand’s pharmaceutical imports came from the United States, Europe, and Canada. Germany was the biggest pharmaceutical exporter to Thailand, trailed by the US, France, at that point Switzerland. The Thai pharmaceutical market was valued at over $5 billion in 2016, making it the second largest market in Southeast Asia. The estimation of Thailand's pharmaceutical market is relied upon to twofold by 2020. Pharmaceutical sales per-capita are also predicted to grow from $75 in 2016 to $125 by 2024.

    Hospitals purchase over two-thirds of all pharmaceuticals sold in Thailand and primarily purchase generics and prescription pharmaceuticals, compared to drugstores which sell over-the-counter (OTC) products. Thailand has one of the biggest restorative tourism advertises on the planet, and more than two million outside patients have flown out to the nation every year since 2013. The continued growth of Thailand’s medical tourism industry has further increased the demand for pharmaceuticals.

Major Universities in Thailand:

  • Kasetsart University
  • Mahidol University
  • Chulalongkorn University
  • Chiang Mai University
  • Naresuan University
  • Khon Kaen University
  • Suranaree University of Technology
  • Prince of Songkla University
  • King Mongkut's University of Technology Thonburi
  • Thammasat University
  • Burapha University
  • Sripatum University
  • Assumption University
  • Rajamangala University of Technology Thanyaburi
  • Srinakharinwirot University
  • Asian Institute of Technology
  • King Mongkut's Institute of Technology Ladkrabang
  • Buriram Rajabhat University
  • Huachiew Chalermprakiet University
  • National Institute of Development Administration

Market in Asia:

    Asia and the Pacific is the area with the second most astounding number of individuals living with HIV on the planet – an expected 5.1 million out of 2015. Three countries - China, India and Indonesia – account for around three-quarters of the total number of people living with HIV in the region. In 2015, there were an estimated 300,000 new infections in the region. Though the period 2010 – 2015 saw an overall decline of 5% in new infections, progress in reducing new infections has slowed in recent years and new HIV infections are on the rise in some countries. The epidemic is largely characterized by concentrated and growing epidemics in a variety of countries, particularly among key affected populations including men who have sex with men, sex workers, people who inject drugs and transgender people. Low national prevalence masks much higher prevalence among these groups and in specific locations, particularly urban areas.

    The HIV plague fluctuates broadly from nation to nation and inside specific nations relying upon setting. This highlights the importance of tailoring responses to each country context. UNAIDS suggests that a ‘location and population’ approach would maximize the impact of scarce resources. Progress in tackling the epidemic varies by geographical area. The pestilences in South and South-East Asia are diminishing, while in East Asia, HIV diseases are rising.

    According to the report Asia Pacific HIV Therapeutics Market, published by Market Data Forecast, the market is projected to reach USD 2.52 billion by 2021, at a CAGR of 2.1% from 2016 to 2021. Asia restorative tourism advertise is expected to cross US$ 14 Billion stamp by 2022.

Asia Pacific HIV Therapeutics Market:

    Drivers & Restraints

    Innovative advancement in HIV diagnosis and therapeutics, increasing number of HIV affected cases and increase in research exercises for developing HIV immunizations are some of the factors driving the market. In addition, expanding mindfulness about the openness of HIV therapeutics in the market and practical steady medicines for HIV are further driving the HIV therapeutics showcase. However, there is a lack of experts and there is no surety of the treatment if it is to work on everyone. Limited medications are another restraint of the market.

Asia Pacific HIV Therapeutics Market:

    Segmentation By drug class

  • Integrase inhibitor
  • Nucleoside/nucleotide reverse transcriptase inhibitor
  • Non-nucleoside turn around transcriptase inhibitor
  • HIV-1 protease inhibitor
  • Pharmacokinetic enhancer

    Section inhibitor Key influenced populaces who are at higher danger of HIV must be the concentration of the HIV reaction in Asia and Pacific if the plague is to be controlled. Creating supportive and safe environments for these groups to seek help and access services is critical.


    

Men who have sex with men (MSM)

    Men who engage in sexual relations with men are one of the key influenced populaces in Asia and the Pacific. In 2015, HIV prevalence among men who have sex with men was higher than 5% in nine of the 19 countries that reported data. Urban areas, for example, Bangkok in Thailand, Yangon in Myanmar and Yogyakarta in Indonesia have assessed HIV predominance rates of in the vicinity of 20% and 29%. One study carried out in Bangkok found that HIV incidence among those aged 18 to 21 was more than double the incidence among men over 30. Around half of all men who engage in sexual relations with men in the district are under 25.

    People who inject drugs (PWID)

    One third of all people who inject drugs (sometimes referred to as PWID) live in Asia and the Pacific. HIV prevalence among this population varies greatly across Asia and the Pacific. In 2015, 20 – 65% of all new grown-up HIV contaminations were among individuals who infuse medicates in Afghanistan, Myanmar, Pakistan and Vietnam. Evidence clearly highlights the link between using clean needles and injecting equipment, and low HIV prevalence. In Katmandu, Nepal, increases in the use of safe needles led to a dramatic reduction in HIV prevalence - from 68% in 2002 to 6.3% in 2011. In Asia and the Pacific, the incarceration rate of people who inject drugs is very high. Combined with a negligible number of harm reduction programmes in prisons, this fuels the HIV epidemic both in prisons and among drug users.

    Transgender populations

    HIV remains a critical concern for many transgender populations across Asia. Especially high HIV pervasiveness rates have been found among transgender populaces in urban areas, for example, Delhi (49%) and Mumbai (42%) in India, and Phnom Penh (37%) in Cambodia. For a lot of these cities, HIV prevalence is much higher among transgender populations in comparison to men who have sex with men. Transgender populations are very often isolated by societies in many Asian and Pacific countries. This has serious knock on effects for obtaining both health-related information and also developing health policies and programmes that effectively support this key affected population.

    Prevention of mother to child transmission (PMTCT)

    Prevention of mother to child transmission (PMTCT) has been significantly scaled-up across Asia and the Pacific. The period between 2009 and 2015 saw a decline of 30% in new HIV infections among children. However, PMTCT treatment coverage throughout the region remains shockingly low at 19%, much lower than other regions of the world including sub-Saharan Africa (59%) and the global average of 62%. Some countries in Asia and the Pacific have made significant progress in PMTCT treatment access including Cambodia (75.3%), Malaysia (85.5%) and Myanmar (90.2%). Furthermore, AIDS-related deaths among children have declined, dropping from 18,000 in 2004 to 15,000 in 2009.

    Malaysia is one example of a country that has made substantial progress with its PMTCT programme, increasing treatment coverage from 68.5% in 2012 to nearly 85.5% in 2013. MTCT rates have also declined, from 18% in 2012 to 8% in 2013. Malaysia demonstrates a clear commitment to eliminating new infections among infants and is leading the way in HIV prevention interventions, ensuring more pregnant mothers living with HIV are receiving the lifesaving treatment they need.

    The HIV epidemic in Asia and the Pacific is complicated, with each country epidemic very different. However, there are some commonalities that highlight areas of critical concern, namely the rising HIV epidemic among men who have sex with men and low HIV treatment coverage. Addressing the legal barriers that increase stigma and discrimination as well as promoting more supportive policies needs to be nationally prioritised for most countries across the region.

    A further challenge is ensuring that funding for the response is sustained. Domestic funding for national HIV responses has increased across Asia and the Pacific in the face of dwindling donor support for the HIV response. In 2014, an estimated US$ 2.4 billion was spent on the HIV response in the region. Countries including China, Malaysia and Thailand are leading the way, nationally funding between 89% to 99% of their HIV responses. The challenge ahead will be for more countries to increase their domestic spending on HIV, ensure that their national responses are sustainable, include prevention and effectively target populations most at risk of HIV.

    Major Universities in Asia:

  • The University of Tokyo
  • Fudan University       
  • Shanghai Jiao Tong University          
  • National Taiwan University   
  • Kyoto University       
  • Peking University      
  • National University of Singapore      
  • Keio University          
  • Tsinghua University   
  • The University of Hong Kong           
  • The Chinese University of Hong Kong         
  • University of Delhi    
  • Seoul National University
  • Nanyang Technological University
  • Osaka University
  • Nanjing University
  • Zhejiang University
  • National Chiao Tung University
  • The Hong Kong University of Science and Technology
  • Tohoku University
  • Hebrew University of Jerusalem
  • King Saud University
  • University of Tehran
  • University of Tsukuba
  • The Hong Kong Polytechnic University                    

Market over the World:

    That HIV infection and AIDS have become a major worldwide public health problem is an excepted fact of life these days. Certainly, the importance, danger and costs of HIV/AIDS cannot be understated or underestimated. While we are fortunate that the dire predictions of the mid-1980s have not come to pass -- at least for the United States and Europe -- the impact of HIV/AIDS of world society is still highly significant. HIV (human immunodeficiency virus) is a virus that attacks the immune system, making it difficult for the body to fight off infection and diseases. HIV infection eventually results in AIDS (acquired immunodeficiency syndrome). This conversion to AIDS may result after 12 or 13 years after the initial infection. Initial HIV symptoms are similar to those of the flu and include fatigue, fever, weight loss, and swollen lymph nodes in the neck, armpits, or groin. Although there is currently no cure for HIV infection, a combination of medications called Highly Active Anti-Retroviral Therapy (HAART), and now referred to as AART, helps prolong life in many people. As noted above, person with HIV infection may live for many years before developing any signs of AIDS. While HIV/AIDS isn’t found in the headlines as much as during the disease’s discovery, more people in the United States are living with HIV/AIDS than ever before. While the incidence of HIV infection in the United States was approximately 0.25% of the population ten to fifteen years ago, it is now approximately 0.47% -- and the population in general has grown. For this reason, it is important to understand the trends in HIV/AIDS epidemiology and the potential impacts on economies and societies as a whole. These trends emphasize the strategic need for preventive approaches, clinical testing technologies and products and new therapeutics. Many market research reports provide such information.

    The global HIV/AIDS market, including branded products and generics, was valued at $11.3 billion in 2010. This market is expected to reach $11.8 billion in 2011 and increase at a 4.6% compound annual growth rate (CAGR) over the 2011-2016 forecast periods to reach $14.1 billion in 2016. The rising prevalence of sexually transmitted diseases has upped the demand for effective drugs. To capitalize on the prevailing trend, a majority of the market players are focusing on research and development activities. Favorable government policies and recent initiatives have further provided boost to their plans of expanding product portfolio, finds Transparency Market Research (TMR) in a new study. According to the report, companies such as Bayer Healthcare, Hoffmann La Roche, Pfizer INC, Bristol-Myers Squibb Co., Gilead Sciences, AbbVie, Inc., Johnson & Johnson, GlaxoSmithKline Plc, Eli Lilly, and Merck & Co., Inc. currently exhibit a strong market presence. Strategies adopted by these companies often prove prolific subsequently influencing the overall market forces.



    The global sexually transmitted diseases drug market is slated for an impressive growth in the coming years. The rising incidence of unprotected sex has upped the prevalence of sexually transmitted diseases, in turn fuelling the demand for effective drugs and treatment procedures. Besides this, the rising awareness among patients as a result of favorable government initiatives and proliferation of educational campaigns has helped the market gain immense impetus in the recent past. Also, lifestyle choices such as having several casual sex partners have spurred the prevalence of STDs worldwide, subsequently, fuelling the demand for sexually transmitted diseases drugs. According to TMR, the global sexually transmitted diseases drug market is forecast to exhibit a CAGR of 11.2% between 2017 and 2025. At this pace, the market is expected to reach US$83,041.3 mn by the end of 2025, from its valuation of US$32,826.3 mn in 2016. Among various therapy classes, antibiotics have emerged as one of the most frequently prescribed products in modern medicine. Regionally, North America emerged dominant, holding the largest share in the global sexually transmitted diseases drug market in 2016.

    Over the course of the forecast period, the global STD drug market is likely to witness impressive growth. Factors such as recent technological advancements leading to precise diagnosis have also spurred the need for effective sexually transmitted diseases drugs. Such demand is directed at achieving speedy disease remission. Also introduction of government reforms and improvement in healthcare infrastructure provide an ideal environment, conducive to the market’s expansion. According to the report, the market is expected to witness much lucrative prospects in Asia Pacific and the Middle East and Africa. Also the rising per capita income of patients and their willingness to spend on advanced medications will augur well for the global sexually transmitted diseases drug market. “The market will significantly benefit from the launch of novel diagnostics and steps taken by governments to boost the healthcare infrastructure,” added a lead TMR analyst. Overall, the rising incidence of various infections such as syphilis, chlamydia, gonorrhea, human papilloma virus, herpes simplex virus, chancroid, vaginitis, and trichomonas vaginalis is expected to fuel he demand for sexually transmitted diseases drugs in the coming years.

The report segments the global sexually transmitted diseases drugs market as:

    Sexually Transmitted Diseases (STDs) Drug Market, by Disease Type

  • Chlamydia
  • Genital herpes
  • Gonorrhea
  • HPV
  • Syphilis
  • HIV/AIDS
  • Others

    Sexually Transmitted Diseases (STDs) Drug Market, by Therapy Class

  • Antibiotics
  • Vaccines
  • Antiviral/Antiretroviral
  • Others

    Sexually Transmitted Diseases (STDs) Drug Market, by Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Others

    Sexually Transmitted Diseases (STDs) Drug Market, by Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

    This review is based on a report, titled “Sexually Transmitted Diseases (STDs) Drug Market (Disease Type – Chlamydia, Gonorrhea, Syphilis, Genital herpes, HPV, and HIV / AIDS; Therapy Class– Antibiotics, Antiviral / Antiretrovirals, and Vaccines) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025.”

    Major Organizations:

  • The Global Fund
  • Center for AIDS Research, UC San Diego
  • UNAIDS
  • The Elton John AIDS Foundation
  • Treatment Action Campaign
  • The Rush Foundation
  • AmfAR
  • Calimmune
  • ViiV Healthcare
  • GeoVax Labs, Inc.
  • Delaney AIDS Research Enterprise (DARE)
  • AIDS Research Alliance
  • Bristol-Myers Squibb
  • Lifespan/Tufts/Brown Center for AIDS Research
  • UC San Diego AIDS Research Institute
  • The Scripps Research Institute

To Collaborate Scientific Professionals around the World

Conference Date June 28-29, 2018
Speaker Oppurtunity Day 1 Day 2
Poster Oppurtunity Available
e-Poster Oppurtunity Available
Venue
&
Hospitality

Updating Soon...

Join The Discussion

Allied Academies Global Conference Directory

Mail us at

Enquiry
std-aids@alliedsummit.org
General Queries
std-aids@alliedsummit.org
Sponsors/Exhibitors
std-aids@alliedsummit.org
More details about sponsorship:sponsors@alliedacademies.com
Copyright © 2017-2018 Allied Academies, All Rights Reserved.